This disclosure generally relates to dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDKl kinases in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
本公开一般涉及双重CLK2/CDK1
抑制剂或更强效、更特异的CLK
抑制剂,用于治疗导致癌症和其他人类疾病发展的剪接体的生殖
细胞系突变。本摘要旨在作为在特定领域进行搜索的扫描工具,不打算限制本发明。